Evofem Biosciences, Inc. CEO Saundra Pelletier Discusses Why $EVFM is a Company to Watch

Detroit, MI

--News Direct--

Evofem Biosciences, Inc., EVFM is a biopharmaceutical company developing & commercializing products to address needs in women's sexual & reproductive health. The Company's 1st FDA-approved product, Phexxi® (lactic acid, citric acid & potassium bitartrate), is a hormone-free prescription contraceptive vaginal gel. The Company may report top-line data in fall 2022 from its registrational Phase 3 EVOGUARD clinical trial evaluating Phexxi for 2 potential new indications – prevention of chlamydia & of gonorrhea in women. Visit phexxi.com & evofem.com.

Contact Details

Benzinga

+1 877-440-9464

info@benzinga.com

Company Website

http://www.benzinga.com

View original content to download multimedia: https://newsdirect.com/news/evofem-biosciences-inc-ceo-saundra-pelletier-discusses-why-evfm-is-a-company-to-watch-625266353

2022 News Direct Corp.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!